

Molecular Aspects of Bone Resorption in β -Thalassemia Major

Najmaldin Saki, Ph.D.¹, Saeid Abroun, Ph.D.^{2*}, Fatemeh Salari, M.Sc.¹, Fakher Rahim, Ph.D.³,
Mohammad Shahjahani, M.Sc.¹, Javad Mohammadi-Asl, Ph.D.⁴

1. Health Research Institute, Research Center of Thalassemia and Hemoglobinopathy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
2. Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3. Health Research Institute, Hearing Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
4. Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding Address: P.O. Box: 14115-331, Department of Hematology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
Email: abroun@modares.ac.ir

Received: 13/Mar/2014, Accepted: 06/Agu/2014

Abstract

β -thalassemia is the most common single gene disorder worldwide, in which hemoglobin β -chain production is decreased. Today, the life expectancy of thalassemic patients is increased because of a variety of treatment methods; however treatment related complications have also increased. The most common side effect is osteoporosis, which usually occurs in early adulthood as a consequence of increased bone resorption. Increased bone resorption mainly results from factors such as delayed puberty, diabetes mellitus, hypothyroidism, ineffective hematopoiesis as well as hyperplasia of the bone marrow, parathyroid gland dysfunction, toxic effect of iron on osteoblasts, growth hormone (GH) and insulin-like growth factor-1 (IGF-1) deficiency. These factors disrupt the balance between osteoblasts and osteoclasts by interfering with various molecular mechanisms and result in decreased bone density.

Given the high prevalence of osteopenia and osteoporosis in thalassemic patients and complexity of their development process, the goal of this review is to evaluate the molecular aspects involved in osteopenia and osteoporosis in thalassemic patients, which may be useful for therapeutic purposes.

Keywords: β -thalassemia, Bone Resorption, Bone Marrow, Osteoblasts, Osteoclasts

Cell Journal (Yakhteh), Vol 17, No 2, Summer 2015, Pages: 193-200

Citation: Saki N, Abroun S, Salari F, Rahim F, Shahjahani M, Mohammadi-Asl J. Molecular aspects of bone resorption in β -thalassemia major. Cell J. 2015; 17(2): 193-200.

Introduction

β -thalassemia is the most common single gene disorder worldwide, in which synthesis of the β -globin chain is decreased, leading to ineffective erythropoiesis (1, 2). Frequent blood transfusions increase the life expectancy of thalassemic patients. However osteopenia and osteoporosis are significant complications that contribute to morbidity of these patients. These two complications are observed in approximately 50% of β -thalassemia patients (3). Subsequent to this complication, bone fracture is noted in 36% of thalassemic patients (4). Osteopenia and osteoporosis are detected by the presence of reduced bone mineral density (BMD), reflecting decreased bone turnover (4).

In thalassemia, osteoporosis is a complicated process affected by several factors. The most important factors for osteoporosis in thalassemia included delayed puberty, diabetes mellitus, hypothyroidism, ineffective hematopoiesis with bone marrow hyperplasia, parathyroid gland dysfunction, toxic effect of iron on osteoblasts and deficiency of growth hormone/insulin-like growth factor-1 (GH/IGF-1). In general, decreased bone density and osteoporosis are the result of a disrupted balance between osteoblasts and osteoclasts (5, 6).

Osteoblasts

Osteoblasts originate from mesenchymal stem

cells (MSCs). Their production is increased by transforming growth factor-beta (TGF- β), basic fibroblast growth factor (bFGF) and bone morphogenetic protein (BMP) (7-9). These cells secrete macrophage-colony stimulating factor (M-CSF), granulocyte macrophage-CSF (GM-CSF), interleukin-1 (IL-1), IL-6 and TGF- β (10). These cytokines are also involved in bone formation because they release alkaline phosphatase (ALP), osteopontin, osteocalcin, collagen and fibronectin (4, 7, 11).

Osteoclasts

These are multinucleate cells that originate from hematopoietic stem cells (HSC) under the effect of M-CSF and the receptor activator of nuclear factor κ B (NF- κ B) ligand (RANKL), causing bone resorption by secretion of matrix metalloproteinase and cathepsin (4, 7, 12, 13).

The RANK/RANKL cytokine system, parathyroid hormone (PTH), sex hormones (such as estrogen and testosterone), inflammatory cytokines, GH/IGF-1, BMP2 protein as well as the wntless related protein/ β -catenin (Wnt/ β -catenin) signaling pathway and iron deposition in the bone marrow are the most common factors that affect the balance between these two cell types (14, 15) (Fig.1).

Cytokine system

Osteoprotegrin/RANKL/RANK

This cytokine system is among the most effective mechanisms in bone reabsorption, which regulates bone density by several factors explained later (16) (Table 1). RANKL has three isoforms and its soluble form is secreted from osteoblasts. RANKL binding to its receptor on precursors and mature osteoclasts triggers the NF- κ B pathway, resulting in differentiation, activation and survival of osteoclasts as well as bone turnover (17, 18). Osteoprotegrin (OPG), an antagonist of RANKL and member of the tumor necrosis factor (TNF) receptor superfamily, is secreted by osteoblasts and prevents the differentiation and activity of osteoclasts (14, 19-22).

In patients with thalassemia, toxicity of iron for osteoblasts along with endocrine effects increase RANKL and decrease OPG, thereby increasing the risk of osteoporosis (23, 24). In chronic diseases, disorders of iron deposition in body organs, endocrine disorders, malignant bone tumors and rheumatoid arthritis disrupt the OPG/RANKL balance which results in inhibition of bone reabsorption (25). Therefore, antibodies against OPG and RANKL (which have an inhibitory effect on osteoclasts) are used in the treatment of bone complications (4, 5).




Fig.1: Important molecules involved in bone resorption in thalassemia. TGF- β ; Transforming growth factor-beta, SOST; Sclerostin, DKK-1; Dickkopf, BMP2; Bone morphogenetic protein-2, GH; Growth hormone, IGF-1; Insulin-like growth factor-1, Wnt; Wingless related protein, LRP5; Low density lipoprotein (LDL)-related protein 5, OPG; Osteoprotegrin, RANKL; Activator of NF- κ B receptor ligand, TNF- α ; Tumor necrotic factor-alpha, IL-6; Interlukin-6, IL-1 α ; Interlukin-1 alpha and COL1A1; Collagen type 1 alpha 1 gene.

Table 1: Overview of molecular mechanisms in bone resorption in thalassemia

Factors	Target (pathway/gene)	Role
PTH	PKA activation and down regulation of OPG/RANKL ratio	Osteoclast activation
17OH-estradiol	Down regulation of JNK pathway on RANKL downstream	Reduction of osteoclast differentiation
Estrogen and testosterone	Influence on OPG and RANKL mRNA	Up regulation of OPG/RANKL ratio
Estrogen	RUNX2 activation	Osteoblastic differentiation
	FasI activation	Osteoclast apoptosis
IL-1 α , IL-6, TNF- α	Initiation of the NF- κ B pathway	Increased osteoclast differentiation and activation
TGF- β	Activation of Smad pathway and induced RUNX2 production	Osteoblast differentiation
IGF-1	Increased OPG, collagen type I, RUNX2, ALP production in HMSC	Osteoblastic differentiation
GH	Increased OPG	Inhibition of osteoclasto-genesis
	Increased BMP2	Induction of osteoblastic differentiation
BMP2	Elevated β -catenin level that results in CBF- α transcription	Osteoblastic differentiation
RUNX2	Wnt canonical pathway	Osteoblastic differentiation
Wnt/ β catenin signaling pathway	β -catenin stabilization	Osteoblastic differentiation
	Up regulation of OPG/RANKL ratio	Reduction of osteoclastic differentiation
DKK-1	Antagonizes canonical Wnt signaling by inhibiting LRP5/6 interaction with Wnt	Inhibition of osteoblastic differentiation
SOST	Inhibition of Wnt signaling	Inhibition of osteoblastic differentiation

PTH; Parathyroid hormone, PKA; Protein kinase A, TGF- β ; Transforming growth factor-beta, SOST; Sclerostin, DKK-1; Dickkopf, BMP2; Bone morphogenetic protein 2, GH; Growth hormone, IGF-1; Insulin-like growth factor 1, Wnt; Wingless related protein, LRP5; Low density lipoprotein (LDL)-related protein 5, OPG; Osteoprotegerin, RANX2; Runt-related transcription factor 2, JNK; Janus kinase, ALP; alkaline phosphatase, HMSC; Human mesenchymal stem cells, NF- κ B; Nuclear factor kappa B, RANKL; Activator of NF- κ B receptor ligand, TNF- α ; Tumor necrotic factor-alpha, IL-6; Interlukin-6 and IL-1 α ; Interlukin-1 alpha.

Inflammatory cytokines

Increased levels of inflammatory cytokines such as IL-1 α , IL-6 and TNF- α (due to iron overload) (3, 10, 11) in the serum of thalassemic patients is inversely related to their bone density (26). The sepro-osteoclastogenic cytokines exert their effects predominantly via the OPG/RANKL system (3, 27). Thus, IL-6, IL-1 α and TNF- α induce cyclooxygenase2 (COX2) and prostaglandin E2 (PGE2) which cause an increase in RANKL and a decrease in OPG, resulting in increased bone resorption (3, 19, 28). Moreover, these cytokines trigger the NF- κ B and Janus kinase (JNK) pathways, ultimately increas-

ing activation and differentiation of osteoclasts (10). IL-6 and TNF- α are also involved in pathogenesis of bone resorption in acute abdominal disease, rheumatoid arthritis and menopause-associated osteoporosis (14). Anti-TNF- α is used to improve bone metabolism in patients with rheumatoid arthritis (29).

Transforming growth factor-beta

Local reduction of TGF- β in the bone marrow is a likely risk factor of osteoporosis in patients with thalassemia (26). TGF- β is a type of receptor tyrosine kinase that phosphorylates Smad and induces the production of Runt-related transcription

factor 2 (RUNX2) in mesenchymal precursors, resulting in osteoblastic differentiation *in vitro* (30, 31). TGF- β causes the death of osteoclasts by reducing the activity of C-JUN factor in the RANKL pathway (7, 32). Most cytokines have paracrine effects. The majority of studies have found no correlation between their circulating concentrations and bone resorption markers (33). Therefore, the best method is to analyze these cytokines in the tissues.

Bone morphogenetic protein 2

Expression of BMP2 is decreased in thalassemic patients with osteoporosis (34). BMP2 is a cytokine from the TGF- β family involved in commitment of mesenchymal precursors to osteoblasts. Local production of BMP2 and TGF- β is associated with increased proliferation and differentiation of osteoblasts (20). BMP2 binding with serine/threonine kinase receptors on the cell surface phosphorylates Smad complex and activates transcription factors effective in osteoblastic differentiation such as RUNX2 and Ostrix (35-37). BMP2 also increases RUNX2 gene transcription by increasing the level of β -catenin, thereby differentiating mesenchymal cells to osteoblasts (38, 39). In addition, BMP2 plays a role in Ostrix activation and mesenchymal differentiation to osteoblasts by activating JNK and P38 factors and triggering the mitogen-activated protein kinase (MAPK) cascade (40-42). P53 inhibits BMP2 and exerts its inhibitory effect by suppressing Ostrix (43).

Endocrine disorders

Growth hormone/insulin-like growth factor-1

Disruption of the GH/IGF-1 pathway is another mechanism in reducing bone density in thalassemic patients (5). GH stimulates the liver to secrete IGF-1. Both hormones have an anabolic role in the bone marrow (16). IGF-1 is mainly released in the liver and GH in the anterior pituitary. In thalassemic patients, iron toxicity for the liver and anterior pituitary possibly reduce serum levels of IGF-1 and GH, respectively (16, 44). However, IGF-1 deficiency is prominently caused by hepatitis C virus (HCV) infection in these patients (45). IGF-1 increases the level of OPG, type I collagen, RUNX2 and ALP in human MSCs (hMSCs) (46) along with inducing the expression of Ostrix (via the MAPK pathway), which result in osteoblastic differentiation. Therefore, there is a positive relationship between the level

of IGF-1 and BMD in thalassemic patients (47). According to research, reduction of IGF-1 plays a role in glucocorticoid-induced osteoporosis (48). GH stimulates the production of BMP and OPG, causing increased proliferation of osteoblasts and inhibition of osteoclast production, respectively (6, 8). GH deficiency has been reported in only 8% of β -thalassemic patients, and is mainly caused by iron overload. In contrast, IGF-1 production is impaired in 72% of patients (45). As a result, introduction of these hormones in thalassemic patients with hormone deficiency is recommended to prevent osteoporosis (3).

Parathyroid hormone

Long-term increase in PTH causes reduction of OPG/RANKL by activating osteoblastic protein kinase A (PKA), thereby increasing the activity of osteoclasts (49, 50).

Sex hormones

A reduced level of sex hormones in thalassemic men with hypogonadism and postmenopausal women can cause osteoporosis. In thalassemic patients, iron deposition in the anterior pituitary disrupts the release of sex hormones and delays puberty in 50% of patients (6, 15).

17OH-estradiol binds its alpha receptor on osteoclasts, decreasing the activity of JNK downstream of RANKL and inducing the production of OPG which results in inhibition of osteoclasts. Therefore, there is a strong correlation between 17OH-estradiol and serum concentrations of OPG and RANKL in thalassemic patients (6, 12, 18). Free estrogen and testosterone in thalassemic patients increase OPG mRNA and decrease RANKL (6, 8, 50). Estrogen also binds the alpha receptor on osteoblasts and osteoclasts, activating RUNX2 in osteoblasts and Fas ligand (FasL) in osteoclasts, which results in increased osteoblastic differentiation and death of osteoclasts (21, 51-54). In addition, androgens and estrogens regulate resorption in bone by regulating cytokines secreted by osteoblasts and stromal cells such as IL1- α , IL-6, TGF- β and PGE2, which control the activity of osteoclasts through paracrine effects (33). Hormone therapy is an approach to prevent osteoporosis in thalassemic patients (3).

Transcription factors

Runt-related transcription factor 2

RUNX2 is an early transcription factor in osteoblastic differentiation. This factor is decreased in thalassemic patients affected by iron deposition in the bone marrow (55). RUNX2 prevents differentiation of MSCs into adipocytes and chondrocytes through the wntless related protein canonical pathway (Wnt-1 pathway), and plays an important role in osteoblastic differentiation and bone formation by increasing BMP2 and induction of Ostrix expression (54, 56).

Ostrix

Reduction of Ostrix in thalassemia is associated with decreased BMD, and it is involved in the pathogenesis of osteoporosis in thalassemic patients (34). It is an essential transcription factor for differentiation of osteoblasts, which is activated by IGF-1, TGF- β and RUNX2, resulting in osteoblastic differentiation (40, 57).

Wnt/ β -catenin signaling pathway proteins

Wnt proteins play an important role in regulating bone mass by affecting osteoblastic maturation and activity. Wnt protein binding with Frizzled (Fz) receptor (a member of the G protein coupled receptors) and LDL related protein co-receptor (LRP) results in signal transduction, stability of β -catenin and its transfer to the nucleus, and eventual transcription of genes associated with osteoblastic differentiation (58-60). Wnt proteins increase OPG/RANKL through the β -catenin dependent canonical pathway (Wnt3a) in osteoblasts, causing an increase in osteoblastic differentiation and suppression of osteoclast production (17, 18, 51).

Dickkopf

DKK-1 is increased in serum of thalassemic patients who have osteoporosis (6), and is associated

with reduced BMD in the lumbar vertebrae and end of the radius (59). Secreted molecular DKK-1 has a cysteine-rich domain at its carboxyl end, which binds LRP5/LRP6 co-receptors and inhibits Wnt binding with these cofactors, preventing osteoblastic differentiation as an antagonist of the canonical Wnt pathway (40, 61, 62). In addition, serum DKK-1 is increased in multiple myeloma (MM) patients with lytic bone lesions, menopause induced osteoporosis, Paget's disease, glucocorticoid induced osteoporosis and estrogen deficiency (39, 63-65). Anti-DKK-1 is used to treat bone loss in patients with MM (66).

Sclerostin

This factor is involved in the incidence of osteoporosis in thalassemic patients. Increased serum levels of this molecule are associated with reduced BMD in thalassemic patients (59). Sclerostin is a secretory molecule and product of the SOST gene which antagonizes LRP4, LRP5 and LRP6 co-receptors, resulting in inhibition of the Wnt canonical pathway and differentiation of osteoblasts (46, 62, 67) (Table 1). Sclerostin is also an antagonist of BMP2 (68), which is increased in MM (in which it is released by plasma cells) and in cancer-induced bone loss (69). Anti-sclerostin is used to treat menopause-related osteoporosis (59).

Genetic factors

Genetic factors play an important role in reduction of bone density and development of osteoporosis in thalassemia (Table 2). One factor is polymorphism in the SP1 region of the collagen type I alpha 1 gene (*COL1A1*), which has an incidence of 90% in thalassemic patients (14, 20). However, it plays no role in osteoporosis in sickle cell patients (70). Polymorphisms in the gene region of vitamin D such as BSM1 (in intron 8) and FOKL (in exon 2) are also associated with reduced bone density in patients with thalassemia and sickle cell anemia (71, 72).

Table 2: Genetic factors involved in osteoporosis in thalassemia

	COLIA-1 polymorphism	Down regulation in procollagen production
Genetic factors	BSM1 polymorphism	
	FOKL polymorphism	Down regulation in vitamin D absorption

COLIA-1; Collagen type 1 alpha 1.

Discussion

Although increased osteoclastogenesis and inadequate osteoblastogenesis can cause an imbalance between bone formation and resorption with a possible decrease in BMD (7), osteoporosis in thalassemic patients is a complicated process influenced by multiple genetic and acquired factors. These factors not only affect the proliferation and activity of osteoblasts and osteoclasts, some such as gastrointestinal absorption disorder play an important role in providing the resources necessary for bone formation. In addition, the person's age, nutritional and physiological conditions are effective in development of bone lesions. Therefore, the presence of a single factor cannot be considered a risk factor for osteoporosis in patients with thalassemia. Rather, a variety of factors must be examined together. In addition, as an osteoporotic skeleton has not been reported to be restored to healthy status in thalassemia, prevention of osteoporosis is of utmost importance in managing β -thalassemic patients. Considering the fact that bone resorption is caused by multiple factors, healthcare vigilance in these patients should be multifactorial. Prescription of calcium can provide adequate calcium levels during skeleton development and can increase bone mass (73-75). Moreover, prescription of vitamin D supplements plays an important role in this process (74, 76). Therefore, thalassemic patients should observe a proper diet as part of their preventive program. Early hormone replacement is the most effective strategy to prevent gonadal deficiency-induced bone loss (77, 78).

In clinical trials, novel therapeutic agents are very promising treatments for bone diseases. These agents include calcitonin and bisphosphonates. Calcitonin is a hormone secreted by the thyroid that inhibits osteoclastic activity. It causes bone pain relief and radiographic improvement after a one year administration in thalassemic patients (79). Also, bisphosphonates inhibit bone resorption and are as beneficial as estrogen, in preventing loss of bone mass (80). Anti-DKK-1 has a pivotal role in bone health for management of bone lesions in MM patients and is a novel therapeutic agent for these patients. However, the clinical trial role of anti-DKK-1 in thalassemic patients should be elucidated (81). Further studies are required to evaluate its effect as well as that of anti-sclerostin on β -thalassemic patients.

Conclusion

This review has discussed a number of genetic and acquired factors that affect bone density in patients with thalassemia. Considering the above factors, hormone therapy, optimal transfusion (preventing precipitation of iron), calcium and vitamin D prescription can be effective in preventing bone lesions.

Given the high prevalence of musculoskeletal disorders in patients with thalassemia and considering the fact that osteopenia and osteoporosis are progressive disorders in these patients, early screening and preventive intervention are of utmost importance. In addition, annual bone density screenings in these patients is recommended. Although the factors mentioned in this article can be important to manage this process, further research in this field is needed.

Acknowledgments

We wish to thank our colleagues at Shafa Hospital and the Research Center of Thalassemia and Hemoglobinopathy of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. The authors declare no conflict of interest.

References

1. Chen FE, Ooi C, Ha SY, Cheung BM, Todd D, Liang R, et al. Genetic and clinical features of hemoglobin H disease in Chinese patients. *N Engl J Med*. 2000; 343(8): 544-550.
2. Ehteram H, Bavarsad MS, Mokhtari M, Saki N, Soleimani M, Parizadeh SM, et al. Prooxidant-antioxidant balance and hs-CRP in patients with beta-thalassemia major. *Clin Lab*. 2014; 60(2): 207-215.
3. Haidar R, Musallam KM, Taher AT. Bone disease and skeletal complications in patients with β thalassemia major. *Bone*. 2011; 48(3): 425-432.
4. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. *Cell*. 1997; 89(2): 309-319.
5. Terpos E, Voskaridou E. Treatment options for thalassemia patients with osteoporosis. *Ann N Y Acad Sci*. 2010; 1202: 237-243.
6. Voskaridou E, Christoulas D, Xirakia C, Varvagiannis K, Boutsikas G, Bilalis A, et al. Serum Dickkopf-1 is increased and correlates with reduced bone mineral density in patients with thalassemia-induced osteoporosis. Reduction post-zoledronic acid administration. *Haematologica*. 2009; 94(5): 725-728.
7. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. *N Engl J Med*. 1995; 332(5): 305-311.
8. Komori T. Regulation of osteoblast differentiation by Runx2. *Adv Exp Med Biol*. 2010; 658: 43-49
9. Azizidoost S, Babashah S, Rahim F, Shahjehani M, Saki

- N. Bone marrow neoplastic niche in leukemia. *Hematology*. 2014; 19(4): 232-238.
10. Riggs BL. The mechanisms of estrogen regulation of bone resorption. *J Clin Invest*. 2000; 106(10): 1203-1204.
 11. Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshminath U, et al. PDGF, TGF- β , and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. *Blood*. 2008; 112(2): 295-307.
 12. Yamaguchi M, Hayashi M, Fujita S, Yoshida T, Utsunomiya T, Yamamoto H, et al. Low-energy laser irradiation facilitates the velocity of tooth movement and the expressions of matrix metalloproteinase-9, cathepsin K, and alpha (v) beta (3) integrin in rats. *J Orthod*. 2010; 32(2): 131-139.
 13. Saba F, Soleimani M, Atashi A, Mortaz E, Shahjehani M, Roshandel E, et al. The role of the nervous system in hematopoietic stem cell mobilization. *Lab Hematol*. 2013; 19(3): 8-16.
 14. Saki N, Abroun S, Farshdousti Hagh M, Asghareh F. Neoplastic bone marrow niche: hematopoietic and mesenchymal stem cells. *Cell J*. 2011; 13(3): 131-136.
 15. Weinberg ED. Role of iron in osteoporosis. *Pediatr Endocrinol Rev*. 2008; 6 Suppl 1: 81-85.
 16. Toumba M, Skordis N. Osteoporosis syndrome in thalassaemia major: an overview. *J osteoporos*. 2010; 2010: 537673.
 17. Srivastava S, Toraldo G, Weitzmann MN, Cenci S, Ross FP, Pacifici R. Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. *J Biol Chem*. 2001; 276(12): 8836-8840.
 18. Pietrapertosa AC, Minenna G, Colella SM, Santeramo TM, Renni R, D'Amore M. Osteoprotegerin and RANKL in the pathogenesis of osteoporosis in patients with thalassaemia major. *Panminerva Med*. 2009; 51(1): 17-23.
 19. Perifanis V, Vyzantiadis T, Vakalopoulou S, Tziomalos K, Garypidou V, Athanassiou-Metaxa M, et al. Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid. *Br J Haematol*. 2004; 125(1): 91-92.
 20. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. *Br J Haematol*. 2004; 127(2): 127-139.
 21. Waalen J. Current and emerging therapies for the treatment of osteoporosis. *J Exp Pharmacol*. 2010; 2: 121-134.
 22. Abroun S, Saki N, Fakher R, Asghari F. Biology and bioinformatics of myeloma cell. *Lab Hematol*. 2012; 18(4): 30-41.
 23. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, et al. Osteoprotegerin and RANKL in the pathogenesis of thalassaemia-induced osteoporosis: new pieces of the puzzle. *J Bone Miner Res*. 2004; 19(5): 722-727.
 24. Salah H, Atfy M, Fathy A, Atfy M, Mansor H, Saeed J. The clinical significance of OPG/sRANKL ratio in thalassaemia patients suffering from osteopenia or osteoporosis in Egyptian patients. *Immunol Invest*. 2010; 39(8): 820-832.
 25. Skordis N, Toumba M. Bone disease in thalassaemia major: recent advances in pathogenesis and clinical aspects. *Pediatr Endocrinol Rev*. 2011; 8 Suppl 2: 300-306.
 26. Salsaa B, Zombos NC. A distinct pattern of cytokine production from blood mononuclear cells in multitransfused patients with beta-thalassaemia. *Clin Exp Immunol*. 1997; 107(3): 589-592.
 27. Morabito N, Russo GT, Gaudio A, Lasco A, Catalano A, Morini E, et al. The "lively" cytokines network in beta-thalassaemia major-related osteoporosis. *Bone*. 2007; 40(6): 1588-1594.
 28. Park YG, Kang SK, Kim WJ, Lee YC, Kim CH. Effects of TGF- β , TNF- α , IL- β and IL-6 alone or in combination, and tyrosine kinase inhibitor on cyclooxygenase expression, prostaglandin E2 production and bone resorption in mouse calvarial bone cells. *Int J Biochem Cell Biol*. 2004; 36(11): 2270-2280.
 29. Kastelan D, Kastelan M, Massari LP, Korsic M. Possible association of psoriasis and reduced bone mineral density due to increased TNF-alpha and IL-6 concentrations. *Med Hypotheses*. 2006; 67(6): 1403-1405.
 30. Lee KS, Kim HJ, Li QL, Chi XZ, Ueta C, Komori T, et al. Runx2 is a common target of transforming growth factor β 1 and bone morphogenetic protein 2, and cooperation between Runx2 and Smad5 induces osteoblast-specific gene expression in the pluripotent mesenchymal Precursor cell line C2C12. *Mol Cell Biol*. 2000; 20(23): 8783-8792.
 31. Lee KS, Hong SH, Bae SC. Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. *Oncogene*. 2002; 21(47): 7156-7163.
 32. Khosla S, Riggs BL. Pathophysiology of age-related bone loss and osteoporosis. *Endocrinol Metab Clin North Am*. 2005; 34(4): 1015-1030.
 33. McLean RR. Proinflammatory cytokines and osteoporosis. *Curr Osteoporos Rep*. 2009; 7(4): 134-139.
 34. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. *Blood*. 2009; 114(1): 181-186.
 35. Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and-2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. *Mol Cancer*. 2007; 6: 71.
 36. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. *Nature*. 2003; 423(6937): 349-355.
 37. Jeon EJ, Lee KY, Choi NS, Lee MH, Kim HN, Jin YH, et al. Bone morphogenetic protein-2 stimulates Runx2 acetylation. *J Biol Chem*. 2006; 281(24): 16502-16511.
 38. Weinstein RS, Manolagas SC. Apoptosis and osteoporosis. *Am J Med*. 2000; 108(2): 153-164.
 39. Anastasilakis AD, Polyzos SA, Avramidis A, Toulis KA, Papatheodorou A, Terpos E. The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis. *Clin Endocrinol (Oxf)*. 2010; 72(6): 752-757.
 40. Ceil AB, Campbell PG. BMP-2 and insulin-like growth factor-I mediate Osterix (Ox) expression in human mesenchymal stem cells via the MAPK and protein kinase D signaling pathways. *J Biol Chem*. 2005; 280(36): 31353-31359.
 41. Katagiri T, Yamaguchi A, Komaki M, Abe E, Takahashi N, Ikeda T, et al. Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage. *J Cell Biol*. 1994; 127(6 Pt 1): 1755-1766.
 42. Lee MH, Kwon TG, Park HS, Wozney JM, Ryoo HM. BMP-2-induced Osterix expression is mediated by Dlx5 but is independent of Runx2. *Biochem Biophys Res Commun*. 2003; 309(3): 689-694.
 43. Wang X, Kua HY, Hu Y, Guo K, Zeng Q, Wu Q, et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. *J Cell Biol*. 2006; 172(1): 115-125.
 44. Vidergor G, Goldfarb AW, Glaser B, Dresner-Pollak R. Growth hormone reserve in adult beta thalassaemia patients. *Endocrine*. 2007; 31(1): 33-37.
 45. Pincelli A, Masera N, Tavecchia L, Perotti M, Perra S, Mariani R, et al. GH deficiency in adult B-thalassaemia major patients and its relationship with IGF-1 production. *Pediatr Endocrinol Rev*. 2011; 8 Suppl 2: 284-289.
 46. Koch H, Jadlowiec JA, Campbell PG. Insulin-like growth factor-I induces early osteoblast gene expression in hu-

- man mesenchymal stem cells. *Stem Cells Dev.* 2005; 14(6): 621-631.
47. Merchant R, Udani A, Puri V, Dcruz V, Patkar D, Karkera A. Evaluation of osteopathy in thalassemia by bone mineral densitometry and biochemical indices. *Indian J Pediatr.* 2010; 77(9): 987-991.
 48. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. *J Clin Invest.* 2005; 115(12): 3318-3325.
 49. Hofbauer L, Kuhne C, Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. *J Musculoskelet Neuronal Interact.* 2004; 4(3): 268-275.
 50. Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. *J Clin Endocrinol Metab.* 2001; 86(7): 3162-3165.
 51. Khalid O, Baniwal SK, Purcell DJ, Leclerc N, Gabet Y, Stallcup MR, et al. Modulation of Runx2 activity by estrogen receptor-alpha: implications for osteoporosis and breast cancer. *Endocrinology.* 2008; 149(12): 5984-5995.
 52. Trivedi R, Goswami R, Chattopadhyay N. Investigational anabolic therapies for osteoporosis. *Expert Opin Investig Drugs.* 2010; 19(8): 995-1005.
 53. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. *Clin Exp Immunol.* 2004; 135(1): 1-8.
 54. Komori T. Regulation of bone development and maintenance by Runx2. *Front Biosci.* 2008; 13: 898-903.
 55. Doyard M, Fatih N, Monnier A, Island ML, Aubry M, Leroyer P, et al. Iron excess limits HHIPL-2 gene expression and decreases osteoblastic activity in human MG-63 cells. *Osteoporos Int.* 2012; 23(10): 2435-2445.
 56. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. *Arch Biochem Biophys.* 2008; 473(2): 139-146.
 57. McGee S, Havens AM, Shiozawa Y, Jung Y, Taichman RS. Effects of erythropoietin on the bone microenvironment. *Growth Factors.* 2012; 30(1): 22-28.
 58. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. *Gene.* 2004; 341: 19-39.
 59. Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, et al. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density. *Horm Metab Res.* 2012; 44(12): 909-913.
 60. Rawadi G, Vayssières B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. *J Bone Miner Res.* 2003; 18(10): 1842-1853.
 61. Semenov MV, Tamai K, Brott BK, Kuhl M, Sokol S, He X. Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6. *Curr Biol.* 2001; 11(12): 951-961.
 62. Semenov M, Tamai K, He X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. *J Biol Chem.* 2005; 280(29): 26770-26775.
 63. Daoussis D, Andonopoulos AP. The emerging role of Dickkopf-1 in bone biology: is it the main switch controlling bone and joint remodeling?. *Semin Arthritis Rheum.* 2011; 41(2): 170-177.
 64. Gaudio A, Pennisi P, Bratengeier C, Torrisi V, Lindner B, Mangiàfico RA, et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. *J Clin Endocrinol Metab.* 2010; 95(5): 2248-2253.
 65. Anastasilakis AD, Polyzos SA, Avramidis A, Toulis K, Giomisi A, Papatheodorou A, et al. Serum Dickkopf-1 levels in postmenopausal women with established osteoporosis before and after treatment with teriparatide. *Bone.* 2009; 44 Suppl 2: S294.
 66. Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C, et al. Bone markers in multiple myeloma. *Eur J Cancer.* 2006; 42(11): 1544-1553.
 67. Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, et al. Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. *J Biol Chem.* 2011; 286(22): 19489-19500.
 68. Robey PG, Young MF, Flanders KC, Roche NS, Kondaiah P, Reddi AH, et al. Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro. *J Cell Biol.* 1987; 105(1): 457-463.
 69. Brunetti G, Oranger A, Mori G, Specchia G, Rinaldi E, Curci P, et al. Sclerostin is overexpressed by plasma cells from multiple myeloma patients. *Ann N Y Acad Sci.* 2011; 1237: 19-23.
 70. Ballas SK, Kesen MR, Goldberg MF, Luty GA, Dampier C, Osunkwo I, et al. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. *ScientificWorldJournal.* 2012; 2012: 949535.
 71. Hamed HM, Galal A, Ghamrawy MEL, Abd ElAzeem K, El Ghoroury EA, Rasheed MA, et al. Vitamin D receptor polymorphisms and indices of bone turnover and bone mass in Egyptian children with sickle cell disease. *Res J Med Med Sci.* 2010; 5(1): 1-7.
 72. Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, DAgruma L, et al. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. *Br J Haematol.* 2000; 111(2): 461-466.
 73. Lindsay R. Hormone replacement therapy for prevention and treatment of osteoporosis. *Am J Med.* 1993; 95(5A): 37S-39S.
 74. Heaney RP. Nutritional factors in osteoporosis. *Annu Rev Nutr.* 1993; 13: 287-316.
 75. Anaploutou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. *Clin Endocrinol (Oxf).* 1995; 42(3): 279-287.
 76. Lindsay R. Prevention and treatment of osteoporosis. *Lancet.* 1993; 341(8848): 801-805.
 77. Filosa A, Di Maio S, Saviano A, Vocca S, Esposito G. Can adrenarche influence the degree of osteopenia in thalassaemic children?. *J Pediatr Endocrinol Metab.* 1996; 9(3): 401-406.
 78. Murphy S, Khaw KT, Sneyd MJ, Compston JE. Endogenous sex hormones and bone mineral density among community-based postmenopausal women. *Postgrad Med J.* 1992; 68(805): 908-913.
 79. Canatan D, Akar N, Arcasoy A. Effects of calcitonin therapy on osteoporosis in patients with thalassemia. *Acta Haematol.* 1995; 93(1): 20-24.
 80. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. *J Clin Invest.* 1991; 88(6): 2095-2105.
 81. Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkatzamanidou M, et al. Dickkopf-1: a suitable target for the management of myeloma bone disease. *Expert Opin Ther Targets.* 2009; 13(7): 839-848.